Molecule intelOpportunity: Moderate0

Recombinanthumanerythropoietin

21 brands · 7 companies · product forms

Opportunity snapshot

Launch attractiveness
39
Market saturation
20
Price room
100
Regulatory risk
0
21
brands
7
companies
Rs 5,149.56
median price
21
price points
340.74x
price spread
90
confidence %

Who competes here

Top companies by brand count · leader share 33%

3 brands · 14%
3 brands · 14%
3 brands · 14%

Price room

Across observed sources and strengths
CheapestRs 1,019.95
MedianRs 5,149.56
Most expensiveRs 347,542.36
Spread340.74×
Sources: DRAP-official

max/min price ratio 340.74x across 21 trusted points (Rs 1019.95-347542.36). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Why this score

Launch attractiveness

40% supply-gap(0) + 25% price-variation(100) + 20% low-competition(80) + 15% supply-disruption(0), damped by confidence(90). Higher = more attractive, less crowded opportunity.

Market saturation

7 canonical companies and 21 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 340.74x across 21 trusted points (Rs 1019.95-347542.36). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Reduced by: no ATC code.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.